Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status approved
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 52076-6247; 62227-019; 68254-6234; 71052-559; 49884-283; 0054-0480; 0078-0566; 0078-0620; 0078-0627; 0378-3096; 0378-3097; 67877-721; 0054-0472; 70377-012; 65129-1324; 71796-012; 0078-0422; 0093-7767; 0093-7768; 49884-119; 51991-821; 63850-0062; 63850-0064; 70377-010; 70377-011; 63850-0059; 67877-718; 0054-0470; 17404-1027; 65727-064; 0078-0567; 51991-824; 63850-0058; 0378-0007; 0378-3098; 0054-0497; 65727-063; 0078-0594; 0078-0628; 49884-158; 0378-0005; 0378-3099; 67877-720; 0054-0471; 52076-6253; 62227-013; 70225-1103; 0078-0415; 0078-0417; 0078-0626; 0054-0482; 52076-6234; 63850-0063; 67877-719; 63850-0061; 0054-0481; 0054-0604; 49884-160; 51991-822; 63850-0060; 0378-0006; 70377-013; 65727-046; 0078-0414; 0093-7766; 49884-125; 49884-127; 49884-128; 49884-159; 51991-823
UNII 9HW64Q8G6G
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal hernia07.16.06.0050.000489%Not Available
Arterial disorder24.03.02.0200.000520%Not Available
Benign neoplasm16.02.02.007--Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000535%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Diabetic complication14.07.03.002; 05.07.03.0020.000229%Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.003562%Not Available
Embolism24.01.01.0090.000382%
Haematotoxicity01.05.01.007; 12.03.01.0250.000382%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.0070.002568%Not Available
Lymphoproliferative disorder16.21.02.001; 01.13.02.001--Not Available
Jaw disorder15.02.04.0090.000596%Not Available
Malnutrition14.03.02.0040.000535%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Metastatic neoplasm16.16.01.0070.000459%Not Available
Neoplasm progression16.16.02.0050.008149%Not Available
Partial seizures17.12.03.0100.000382%Not Available
Spondylitis15.01.09.002--Not Available
Sudden hearing loss04.02.01.0090.000229%Not Available
Cardiac valve disease02.07.02.0010.000382%Not Available
White blood cell disorder01.02.05.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.031586%
Gastrointestinal ulcer07.04.04.0020.000336%Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Renal injury20.01.03.015; 12.01.05.0010.000489%Not Available
Renal neoplasm20.01.04.004; 16.08.03.0010.000459%Not Available
The 25th Page    First    Pre   25 26 27 28 29    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene